Advanced prostate cancer cases in California are rising faster than the national average, according to a UCSF study. Experts ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
2don MSN
When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...
The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly se ...
Sebastian Kaulitzki – stock.adobe.com “Without screening, the number of men diagnosed with advanced prostate cancer – when treatments are less effective – increases fast.” Fox News ...
The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study.
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including ...
NEW YORK, NY, USA I 13, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback